Industry Growth Program Completion Marks Key Commercial Milestone

Written By Ketim Technologies

Brisbane, Australia – February 19, 2026 – Ketim Technologies has successfully completed the 2025 Industry Growth Program (IGP), delivered by AusBiotech and funded by the Department of Industry, Science and Resources.

The Industry Growth Program supports high-potential Australian biotechnology and medical technology companies through structured commercial capability development, covering regulatory strategy, intellectual property, investment readiness, clinical trial design, and scale-up manufacturing.

As part of the cohort, Ketim was paired with experienced industry mentor Tony Aitchison, working alongside program leaders including Tamlyn O’Connor to refine its commercial strategy, strengthen investor positioning, and advance applications for targeted industry funding.

Participation in the Industry Growth Program complements Ketim’s ongoing regulatory planning, grant submissions, and international investor engagement as the company advances development of its predictive blood-based diagnostic for postpartum depression.

A video interview featuring Dr. Yates as part of the 2025 cohort is available through AusBiotech.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au

Ketim Technologies

https://www.ketim.com.au
Previous

Engagement with U.S. Consul General Strengthens Australia–U.S. Expansion Pathway
Next

Ketim Technologies Awarded Advance Queensland Ignite Spark Grant to Progress Perinatal Mental Health Diagnostic